financetom
Business
financetom
/
Business
/
Coronavirus impact: DHFL bid submission deadline extended to May 7
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Coronavirus impact: DHFL bid submission deadline extended to May 7
Apr 3, 2020 3:28 AM

Lenders to troubled mortgage financier Dewan Housing Finance Limited (DHFL) have agreed to extend the deadline to submit bids for the company by 21 days to May 7 amid the Coronavirus related lockdown, people aware of the decision told CNBC-TV18.

The extension comes after several suitors approached the lenders about delays being faced in putting together a bid amid restricted activities during the lockdown period. The original deadline to submit these binding bids was set for April 16, said bankers involved in discussions.

If the lockdown related difficulties persist, the creditors' committee may be forced to consider another extension, added one of the people quoted above.

The deadline extension was communicated to all 22 shortlisted suites via the Virtual Data Room (VRD) yesterday, another person added.

The 180-day time period allowed for resolution under the Insolvency and Bankruptcy Code ends on May 31st for DHFL. The creditors' committee may also seek another 90 days extension permitted under IBC for the resolution, given the delays in the process, CNBC-TV18 had reported earlier.

22 suitors have been shortlisted from among 24 that ad submitted Expressions of Interest to acquire the company, CNBC-TV18 had reported.

These include corporates like the Adani Group, Welspun Group, Piramal Enterprises, Hero Fincorp, private equity giants like Blackstone fund, Warburg Pincus, Barings, Cerberus, KKR, asset reconstruction companies like ARCIL, SSG Capital, Phoenix ARC among others.

DHFL is the first financial services company to be admitted into NCLT under the Insolvency and Bankruptcy Code for resolution under the newly introduced Section 227 of the IBC.

Financial creditors alone have made claims of over Rs 86,892 crore against the company under IBC, of which Rs 80,979 crore of claims have already been admitted.

First Published:Apr 3, 2020 12:28 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Jazz Pharmaceuticals Q3 revenue beats estimates
Jazz Pharmaceuticals Q3 revenue beats estimates
Nov 5, 2025
Overview * Jazz Pharmaceuticals ( JAZZ ) Q3 revenue grows 7% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats consensus, reflecting robust operational performance * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln Outlook * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln * Jazz Pharmaceuticals ( JAZZ ) expects top-line data from zanidatamab...
Delaware judge says she will not block Metsera from ending Pfizer deal 
Delaware judge says she will not block Metsera from ending Pfizer deal 
Nov 5, 2025
WILMINGTON, Delaware, Nov 5 (Reuters) - A Delaware judge said on Wednesday she would reject a request by Pfizer ( PFE ) to temporarily block Metsera ( MTSR ) from terminating its takeover deal with Pfizer ( PFE ), allowing Metsera ( MTSR ) to proceed instead with a higher $10 billion deal from Novo Nordisk. ...
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
Nov 5, 2025
MIAMI--(BUSINESS WIRE)-- World Kinect Corporation ( WKC ) today announced that it has completed its previously announced acquisition of the Trip Support Services (TSS) division of Universal Weather and Aviation. Universal Weather, headquartered in Houston, Texas, has been a pioneer in trip support services with deep expertise in international travel regulations, logistics, and supply chain management. Its trip support business...
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Nov 5, 2025
Overview * Cytokinetics ( CYTK ) Q3 net loss widens to $306.2 mln, driven by debt conversion expense * Company reports Q3 revenue of $1.9 mln, up from $0.5 mln last year * Cytokinetics ( CYTK ) prepares for potential U.S. launch of aficamten pending FDA approval Outlook * Company expects EMA decision on aficamten MAA in 1H 2026 *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved